

## LEGISLATIVE FISCAL OFFICE Fiscal Note

Fiscal Note On: **SB 82** SLS 22RS

Bill Text Version: ENGROSSED

Opp. Chamb. Action:

Proposed Amd.: Sub. Bill For.:

Date: April 8, 2022 8:47 AM Author: MILLS, FRED

Dept./Agy.: LDH/Medicaid

Subject: pharmacy reimbursement Analyst: Shawn Hotstream

MEDICAID EG INCREASE GF EX See Note Provides relative to Medicaid reimbursement for pharmacy services. (8/1/22)

Page 1 of 1

274

Proposed law requires the department to enhance reimbursement for pharmacy services using funds paid to the state in the form of a prescription drug rebate through the Medicaid drug rebate program. By January 1, 2023, the department shall file a state plan amendment with the Centers for Medicare and Medicaid Services (CMS) to provide that a pharmacist or pharmacy shall be eligible for enhanced reimbursement which equals or approximates 100% of the appropriate reasonable cost of providing pharmacy services, including but not limited to the actual acquisition cost of drugs and devices.

| EXPENDITURES   | 2022-23    | 2023-24    | 2024-25        | 2025-26    | 2026-27    | 5 -YEAR TOTAL |
|----------------|------------|------------|----------------|------------|------------|---------------|
| State Gen. Fd. | INCREASE   | INCREASE   | INCREASE       | INCREASE   | INCREASE   |               |
| Agy. Self-Gen. | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Ded./Other     | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Federal Funds  | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Local Funds    | <u>\$0</u> | <u>\$0</u> | <u>\$0</u>     | <u>\$0</u> | <u>\$0</u> | <u>\$0</u>    |
| Annual Total   |            |            |                |            |            |               |
| REVENUES       | 2022-23    | 2023-24    | <u>2024-25</u> | 2025-26    | 2026-27    | 5 -YEAR TOTAL |
| State Gen. Fd. | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Agy. Self-Gen. | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Ded./Other     | \$0        | \$0        | \$0            | \$0        | \$0        | <b>\$0</b>    |
| Federal Funds  | \$0        | \$0        | \$0            | \$0        | \$0        | \$0           |
| Local Funds    | <u>\$0</u> | <u>\$0</u> | <u>\$0</u>     | <u>\$0</u> | <u>\$0</u> | <u>\$0</u>    |
| Annual Total   | \$0        | <b>\$0</b> | \$0            | \$0        | \$0        | \$0           |

## **EXPENDITURE EXPLANATION**

This measure is anticipated to increase reimbursement to pharmacy providers from the Medicaid program as a result of requiring payment up to 100% of appropriate reasonable cost of actual acquisition cost of drugs (actual cost the pharmacy provider pays to acquire the drug product from a manufacturer). This measure further requires the cost increase to be covered with drug rebates (state portion) received by the department. The LFO has requested additional information in order to calculate a fiscal impact of this measure, including the actual number of pharmacy invoices that would have to be reviewed annually by LDH. LDH currently reimburses pharmacy providers for their cost of purchasing the drug product (ingredient) based on a national average (National Average Drug Acquisition Cost, or NADAC). To the extent the Medicaid reimbursement is lower than the actual cost of the pharmacy to purchase, this measure appears to require an additional reimbursement to the pharmacist up to 100% of their purchase cost.

Note: LDH has indicated that changing the reimbursement methodology from a NADAC model to a Louisiana Average Acquisition Cost (AAC) model would meet the provisions of this bill, based on the assumption that average acquisition costs of pharmacies in Louisiana is a more accurate indication of actual cost to acquire the drug than based on a national average. Based on analysis by Myers and Stauffer (CPA firm contracted with LDH), changing to an AAC reimbursement model will result in \$14.M in reduced payments to pharmacy providers (for Brand and Generic drug products).

## **REVENUE EXPLANATION**

There is no anticipated direct material effect on governmental revenues as a result of this measure.

| <u>Senate</u><br>13.5.1 >= | <u>Dual Referral Rules</u><br>\$100,000 Annual Fiscal Cost {S & H} | House                                   | Evan          | Brasseaux |
|----------------------------|--|---|---------------|-----------|
|                            | \$500,000 Annual Tax or Fee  | 6.8(G) >= \$500,000 Tax or Fee Increase | Evan Brasseau | _         |